Melbourne, Aug 11, 2008 (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced the commencement of dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus (HRV). HRV is the major cause of the common cold and is associated with clinical complications for patients with asthma, cystic fibrosis, chronic obstructive pulmonary disease or a compromised immune function.
